Sino Biopharmaceutical Li... (SBMFF)
OTC: SBMFF
· Real-Time Price · USD
0.99
0.00 (0.10%)
At close: Aug 13, 2025, 12:40 PM
0.99
0.00%
After-hours: Aug 14, 2025, 08:00 PM EDT
Sino Biopharmaceutical Income Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 28.87B | 22.37B | 23.51B | 23.21B | 19.32B | 26.11B | 26.07B | 26.03B | 28.24B | 27.7B | 27.22B | 26.86B | 26.13B | 25.35B | 24.67B |
Cost of Revenue | 5.34B | 4.09B | 4.47B | 4.68B | 3.37B | 4.78B | 4.64B | 4.49B | 5.67B | 5.54B | 5.4B | 5.33B | 5.15B | 5.14B | 5.33B |
Gross Profit | 23.53B | 18.28B | 19.04B | 18.54B | 15.95B | 21.32B | 21.43B | 21.54B | 22.57B | 22.16B | 21.82B | 21.53B | 20.98B | 20.21B | 19.34B |
Operating Income | 6.28B | 4.94B | 5.17B | 4.93B | 3.99B | 5.35B | 5.37B | 5.39B | 5.33B | 4.77B | 4.97B | 4.63B | 4.74B | 5.18B | 4.94B |
Interest Income | n/a | n/a | 3.08M | 6.15M | 21.67M | 37.18M | 56.46M | 75.73M | 146.42M | 217.12M | 254.08M | 251.27M | 191.26M | 159.53M | 175.69M |
Pretax Income | 5.28B | 4.45B | 5.23B | 5.03B | 3.67B | 4.68B | 4.95B | 5.21B | 8.56B | 11.35B | 17.61B | 18.57B | 16.05B | 13.44B | 6.59B |
Net Income | 3.5B | 3.26B | 3.65B | 2.77B | 1.09B | 1.4B | 1.73B | 2.06B | 5.3B | 8.05B | 13.66B | 14.61B | 12.92B | 10.8B | 5.2B |
Selling & General & Admin | 12.16B | 9.5B | 10.07B | 9.87B | 8.4B | 11.22B | 11.46B | 11.71B | 12.7B | 12.85B | 12.67B | 12.7B | 12.72B | 12.7B | 12.17B |
Research & Development | 5.09B | 3.83B | 3.76B | 3.65B | 3.41B | 4.55B | 4.4B | 4.24B | 4.17B | 4.01B | 3.76B | 3.75B | 3.46B | 2.87B | 2.67B |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -11.98M | -248.5M | -93.95M |
Operating Expenses | 17.25B | 13.34B | 13.83B | 13.52B | 12.27B | 16.64B | 16.51B | 16.37B | 14.16B | 11.03B | 9.07B | 7.82B | 10.22B | 12.05B | 13.23B |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 75.56M | 147.22M | 147.22M | 238.36M | 246.69M |
Selling & Marketing Expenses | 10.08B | 7.94B | 8.49B | 8.28B | 7.14B | 9.44B | 9.62B | 9.81B | 10.48B | 10.6B | 10.34B | 10.52B | 10.2B | 10.03B | 9.54B |
Cost & Expenses | 22.58B | 17.43B | 18.3B | 18.19B | 15.63B | 21.43B | 21.14B | 20.85B | 19.82B | 16.57B | 14.47B | 13.15B | 15.37B | 17.2B | 18.56B |
Income Tax Expense | 735.27M | 674.68M | 876.46M | 831.79M | 547.77M | 650.07M | 673.39M | 696.72M | 984.17M | 1.19B | 1.8B | 1.96B | 1.54B | 1.47B | 907.07M |
Shares Outstanding (Basic) | 17.24B | 17.24B | 20.32B | 20.32B | 18.55B | 18.57B | 18.57B | 16.05B | 21.03B | 20.87B | 20.87B | 20.52B | 20.52B | 19.26B | 20.62B |
Shares Outstanding (Diluted) | 18.18B | 18.18B | 18.41B | 18.47B | 18.57B | 18.56B | 18.56B | 18.91B | 18.91B | 19.12B | 19.12B | 19.28B | 19.28B | 19.29B | 19.29B |
EPS (Basic) | 0.18 | 0.16 | 0.18 | 0.14 | 0.06 | 0.07 | 0.08 | 0.10 | 0.26 | 0.39 | 0.69 | 0.73 | 0.66 | 0.56 | 0.27 |
EPS (Diluted) | 0.19 | 0.18 | 0.20 | 0.15 | 0.06 | 0.08 | 0.09 | 0.11 | 0.28 | 0.42 | 0.71 | 0.76 | 0.67 | 0.56 | 0.27 |
EBITDA | 6.13B | 5.04B | 5.77B | 5.6B | 4.74B | 6.35B | 6.3B | 6.25B | 6.16B | 5.57B | 12.01B | 13.16B | 13.06B | 13.32B | 6.9B |
EBIT | 5.17B | 4.32B | 4.99B | 4.77B | 3.9B | 5.26B | 5.32B | 5.39B | 5.33B | 4.77B | 11.4B | 12.74B | 13.26B | 13.73B | 6.89B |
Depreciation & Amortization | 956.76M | 721.76M | 786.85M | 851.95M | 857.75M | 1.1B | 986.38M | 868.56M | 832.95M | 797.33M | 808.95M | 1.01B | 1.19B | 1.34B | 1.5B |